PUBLISHER: DelveInsight | PRODUCT CODE: 1129035
PUBLISHER: DelveInsight | PRODUCT CODE: 1129035
DelveInsight's 'Progressive pulmonary fibrosis (PPF) - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Progressive pulmonary fibrosis (PPF), historical and forecasted epidemiology as well as the Progressive pulmonary fibrosis (PPF) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Progressive pulmonary fibrosis (PPF) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Progressive pulmonary fibrosis (PPF) market size from 2019 to 2032. The Report also covers current Progressive pulmonary fibrosis (PPF) treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
Progressive pulmonary fibrosis (PPF) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.
Progressive pulmonary fibrosis (PPF) are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs.
Progressive pulmonary fibrosis (PPF) Diagnosis
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), is key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive pulmonary fibrosis (PPF) is calculated on the basis of FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.
The differential diagnosis of Interstitial Lung Diseases requires a multidisciplinary approach, usually involving pulmonologist, radiologist, and pathologist. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging and if required, lung biopsy.
Continued in the report…..
Progressive pulmonary fibrosis (PPF) Treatment
Treatment for Interstitial Lung Diseases varies depending on the type of Interstitial Lung Disease diagnosed and the severity. Lung damage from Interstitial Lung Diseases is often irreversible and progressive, so treatment normally centers on relieving symptoms, improving quality of life and slowing the disease's progression. Medications, such as corticosteroids, can be used to decrease inflammation in the lungs.
Nintedanib (Ofev) is the only approved drug in the Progressive pulmonary fibrosis (PPF) treatment landscape. Along with Ofev the current market is mainly attributed to corticosteroids and immunosuppressant for treatment. Novel uses of antifibrotic therapies are emerging due to a paucity of evidence-based treatments for multiple Interstitial Lung Disease subtypes. The market is anticipates launch of several emerging therapies in the Progressive pulmonary fibrosis (PPF) treatment domain in the forecast period.
Continued in the report…..
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Key Findings
The epidemiology segment also provides the Progressive pulmonary fibrosis (PPF) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Progressive pulmonary fibrosis (PPF) report encloses the detailed analysis of Progressive pulmonary fibrosis (PPF) drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Progressive pulmonary fibrosis (PPF) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.
Progressive pulmonary fibrosis (PPF) Emerging Drugs
BI 1015550: Boehringer Ingelheim
BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects being developed by Boehringer Ingelheim. It has the potential to address both pulmonary fibrosis - an irreversible scarring of lung tissue that negatively impacts lung function - and inflammation associated with Progressive pulmonary fibrosis (PPF) (ILDs). BI 1015550 represents the first molecule in the class of PDE4B inhibitors that is being studied for IPF and other progressive fibrosing ILDs. Breakthrough Therapy Designation was granted to BI 1015550 in February 2022 for the treatment of idiopathic pulmonary fibrosis (IPF) by the US Food and Drug Administration (FDA).
Products detail in the report…
List to be continued in the report…
Progressive pulmonary fibrosis (PPF) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.
ILD and its progressing forms, form a substantial proportion of disabling chronic lung disease leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PPFs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PPFs. These unmet treatment gaps accentuates the launch of emerging therapies.
In the upcoming treatment landscape, there are plethora of companies investigating agents for use in the PPF which includes Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd., Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB. There are many more pharma companies which are conducting clinical trials for therapies of PPF.
Continued in the report…..
Key Findings
This section provides the total Progressive pulmonary fibrosis (PPF) market size and market size by therapies in the United States.
The total Progressive pulmonary fibrosis (PPF) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Progressive pulmonary fibrosis (PPF) market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the Progressive pulmonary fibrosis (PPF) or expected to get launched in the market during the study period 2019-2032. The analysis covers Progressive pulmonary fibrosis (PPF) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Progressive pulmonary fibrosis (PPF) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Progressive pulmonary fibrosis (PPF) emerging therapies.
Reimbursement Scenario in Progressive pulmonary fibrosis (PPF)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Progressive pulmonary fibrosis (PPF) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Reports
Key Questions
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: